Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 27, 2026 09:00 ET | Source: Nextech Systems, Inc.

Nextech Pioneers New Era in Clinical Documentation with Launch of AI-Powered Cora Scribe

Tampa, Fla., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Specialty-specific clinical documentation requires more than a generic, automated note taker to truly improve the charting process. Today, Nextech – an...
January 27, 2026 09:00 ET | Source: Muscular Dystrophy Association

Organizations Join Forces to Map How Human Muscle Regenerates

New York, Jan. 27, 2026 (GLOBE NEWSWIRE) -- A pivotal scientific collaboration born out of the Muscular Dystrophy Association’s (MDA) Muscle Regeneration Summit is advancing a first-of-its-kind...
January 27, 2026 09:00 ET | Source: MarketsandMarkets Research Pvt. Ltd.

Global Clinical Mass Spectrometry Market to Reach USD 3.31 Billion by 2031 | MarketsandMarkets™

Delray Beach, FL, Jan. 27, 2026 (GLOBE NEWSWIRE) -- The global clinical mass spectrometry market is projected to reach USD 3.31 billion in 2031 from USD 1.92 billion in 2025 at a CAGR of 9.5%. What...
January 27, 2026 09:00 ET | Source: Truveta

Truveta launches real-time clinical trials solution to accelerate study design, enrollment, and evidence generation

BELLEVUE, Wash., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Truveta today announced the launch of its new clinical trials solution that enables trial sponsors to design, optimize, and execute clinical...
January 27, 2026 08:50 ET | Source: Myriad Genetics, Inc.

Myriad Advances MRD Commercialization Timeline, Bolstered by New Study Data

Myriad advances Precise MRD toward a March 2026 launch, backed by new breast and colorectal cancer data showing ultrasensitive ctDNA detection.
January 27, 2026 08:45 ET | Source: Ernexa Therapeutics Inc.

Ernexa Therapeutics Selected as One of Only Ten Global Companies for Prestigious JETRO Japan Entry Acceleration Program

CAMBRIDGE, Mass., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune...
January 27, 2026 08:30 ET | Source: CytoDyn Inc.

CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer

VANCOUVER, Washington, Jan. 27, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized...
January 27, 2026 08:30 ET | Source: Quoin Pharmaceuticals, Inc.

Quoin Pharmaceuticals Announces Submission to Japanese MHLW for Orphan Drug Designation for QRX003 in Netherton Syndrome

Confirmation Received from MHLW That QRX003 Qualifies for Both Orphan Drug Designation and Fast Track Regulatory Review Status Quoin Initiating the Establishment of a Japanese Subsidiary to...
January 27, 2026 08:30 ET | Source: TRIMEDX

TRIMEDX named recipient of Modern Healthcare’s Best in Business Award in Cybersecurity category

Indianapolis, Indiana, Jan. 27, 2026 (GLOBE NEWSWIRE) -- TRIMEDX―a leading independent clinical asset management company delivering clinical engineering services, clinical asset informatics, and...
January 27, 2026 08:30 ET | Source: Imviva Biotech

Imviva Biotech Receives FDA Orphan Drug Designation for CTD402 for the Treatment of T-Cell Leukemia and Lymphoma

BOSTON, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Imviva Biotech, a clinical-stage biotechnology company developing next-generation allogeneic CAR-T cell therapies, today announced that the U.S. Food and...